FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3201609279> ?p ?o ?g. }

• W3201609279 abstract "Background: The risks of all-cause mortality, cardiovascular diseases (CVD), end-stage renal diseases (ESRD), and severe hypoglycaemia (SH) among obese patients with T2DM initiating novel glucose-lowering medications (SGLT2i and GLP-1RA) and those undergoing bariatric surgery were unknown. Methods: This was a population-wide retrospective cohort study. Data were collected from the Hong Kong Hospital Authority database from 2006 to 2017. Generalized matching weights of propensity score was applied to balance out baseline covariates of obese patients with T2DM who underwent bariatric surgery, or initiated SGLT2i or GLP-1RA. Hazard ratios (HRs) for CVD, ESRD, and mortality from any causes were assessed among three groups using Cox proportional hazard models. Findings: Over a median follow-up period of 14 months with 2916·25 person-years, incidence of CVD was the highest in SGLT2i group (7·156/100 person-years). Incidences of ESRD and all-cause mortality were the highest in bariatric surgery group (0·453 and 2·316/100 person-years). SGLT2i users had not significantly lower risk of all-cause mortality (HR=0·343, 95%CI=0·089-1·326, p=0·121), CVD (HR=1·125, 95%CI=0·576-2·198, p=0·729), ESRD (HR=0·480, 95%CI=0·109-2·107, p=0·331) and SH (HR=2·654, 95%CI=0·713-9·871, p=0·145) than bariatric surgery candidates. When comparing with bariatric surgery, GLP-1RA was not associated with significant reduction in risks of all-cause mortality (HR=0·350, 95%CI=0·117-1·045, p=0·060), CVD (HR=0·722, 95%CI=0·327-1·596, p=0·421), ESRD (0·251, 95%CI=0·034-1·836, p=0·173) and SH (1·923, 95%CI=0·418-8·853, p=0·401) events. Patients undergoing bariatric surgery had significantly greater improvement in BMI (-6·879kg/m2 , -0·787kg/m2 , -1·160kg/m2 , p<0·001), HbA1c (-1·723%, -0·875%, -0·607%, p<0·001), fasting glucose (-2·699, -1·345, -0·386, p<0·001) and triglyceride (-0·746, -0·204, -0·007, p<0·001) after 12-month, and higher 12-month cumulative direct healthcare costs (US34,736, US11,266, US10,929, p<0·001) than SGLT2i and GLP-1RA users. Interpretation: Among obese patients with T2DM, risks of all-cause mortality, CVD, ESRD and SH did not differ across three groups over the study period. Beneficial weight loss, metabolic outcomes, and higher direct healthcare costs at 12-month after bariatric surgery were observed. Funding Statement: This study was funded by the Health and Medical Research Fund Research Fellowship Scheme, Food and Health Bureau, Hong Kong SAR (Ref No. #02160087).Declaration of Interests: Dr Wong reports receipt of research funding from the EuroQoL Group Research Foundation, the Hong Kong Research Grants Council, and the Hong Kong Health and Medical Research Fund. Dr Man reports receipt of CW Maplethorpe Fellowship. Dr Chan reports receipt of research funding from Bristol-Myers Squibb, Pfizer, Janssen, Takeda Pharmaceuticals, the Hong Kong Beat Drugs Fund Association, the Hong Kong Research Grants Council, and the Hong Kong Health and Medical Research Fund. Prof Wong reports receipt of research funding from BristolMyers Squibb, Pfizer, Janssen, the Hong Kong Research Grants Council, and the Hong Kong Health and Medical Research Fund. Prof Lam reports receipt of research funding from the Hong Kong Research Grants Council, the Hong Kong Health and Medical Research Fund, and the Kerry Group and Kouk Foundation Endowed Primary Care Research Fund of the University of Hong Kong. No other disclosures were reported.Ethics Approval Statement: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Ethics approval of this study was granted by the Institutional Review Board of the University of Hong Kong /Hospital Authority Hong Kong West Cluster (HKU/HA HKW IRB) (Ref No. UW 16-1018)." @default.
• W3201609279 created "2021-09-27" @default.
• W3201609279 creator A5025936391 @default.
• W3201609279 creator A5028633730 @default.
• W3201609279 creator A5029330906 @default.
• W3201609279 creator A5030389292 @default.
• W3201609279 creator A5032635333 @default.
• W3201609279 creator A5041610413 @default.
• W3201609279 creator A5043812892 @default.
• W3201609279 creator A5045925648 @default.
• W3201609279 creator A5048766394 @default.
• W3201609279 creator A5064332338 @default.
• W3201609279 creator A5076758172 @default.
• W3201609279 creator A5077256370 @default.
• W3201609279 creator A5081969615 @default.
• W3201609279 date "2020-01-01" @default.
• W3201609279 modified "2023-10-18" @default.
• W3201609279 title "SGLT2 Inhibitors, GLP-1 Receptor Agonists, or Bariatric Surgery and Risks of All-Cause Mortality, Cardiovascular Diseases, End-Stage Renal Diseases, and Severe Hypoglycemia in Obese Patients with Type 2 Diabetes Mellitus" @default.
• W3201609279 doi "https://doi.org/10.2139/ssrn.3551370" @default.
• W3201609279 hasPublicationYear "2020" @default.
• W3201609279 type Work @default.
• W3201609279 sameAs 3201609279 @default.
• W3201609279 citedByCount "0" @default.
• W3201609279 crossrefType "journal-article" @default.
• W3201609279 hasAuthorship W3201609279A5025936391 @default.
• W3201609279 hasAuthorship W3201609279A5028633730 @default.
• W3201609279 hasAuthorship W3201609279A5029330906 @default.
• W3201609279 hasAuthorship W3201609279A5030389292 @default.
• W3201609279 hasAuthorship W3201609279A5032635333 @default.
• W3201609279 hasAuthorship W3201609279A5041610413 @default.
• W3201609279 hasAuthorship W3201609279A5043812892 @default.
• W3201609279 hasAuthorship W3201609279A5045925648 @default.
• W3201609279 hasAuthorship W3201609279A5048766394 @default.
• W3201609279 hasAuthorship W3201609279A5064332338 @default.
• W3201609279 hasAuthorship W3201609279A5076758172 @default.
• W3201609279 hasAuthorship W3201609279A5077256370 @default.
• W3201609279 hasAuthorship W3201609279A5081969615 @default.
• W3201609279 hasConcept C126322002 @default.
• W3201609279 hasConcept C134018914 @default.
• W3201609279 hasConcept C141071460 @default.
• W3201609279 hasConcept C207103383 @default.
• W3201609279 hasConcept C2777180221 @default.
• W3201609279 hasConcept C2779134260 @default.
• W3201609279 hasConcept C2780668416 @default.
• W3201609279 hasConcept C2781308992 @default.
• W3201609279 hasConcept C2908647359 @default.
• W3201609279 hasConcept C2910068830 @default.
• W3201609279 hasConcept C3019040382 @default.
• W3201609279 hasConcept C44249647 @default.
• W3201609279 hasConcept C50382708 @default.
• W3201609279 hasConcept C511355011 @default.
• W3201609279 hasConcept C544821477 @default.
• W3201609279 hasConcept C555293320 @default.
• W3201609279 hasConcept C71924100 @default.
• W3201609279 hasConcept C72563966 @default.
• W3201609279 hasConcept C99454951 @default.
• W3201609279 hasConceptScore W3201609279C126322002 @default.
• W3201609279 hasConceptScore W3201609279C134018914 @default.
• W3201609279 hasConceptScore W3201609279C141071460 @default.
• W3201609279 hasConceptScore W3201609279C207103383 @default.
• W3201609279 hasConceptScore W3201609279C2777180221 @default.
• W3201609279 hasConceptScore W3201609279C2779134260 @default.
• W3201609279 hasConceptScore W3201609279C2780668416 @default.
• W3201609279 hasConceptScore W3201609279C2781308992 @default.
• W3201609279 hasConceptScore W3201609279C2908647359 @default.
• W3201609279 hasConceptScore W3201609279C2910068830 @default.
• W3201609279 hasConceptScore W3201609279C3019040382 @default.
• W3201609279 hasConceptScore W3201609279C44249647 @default.
• W3201609279 hasConceptScore W3201609279C50382708 @default.
• W3201609279 hasConceptScore W3201609279C511355011 @default.
• W3201609279 hasConceptScore W3201609279C544821477 @default.
• W3201609279 hasConceptScore W3201609279C555293320 @default.
• W3201609279 hasConceptScore W3201609279C71924100 @default.
• W3201609279 hasConceptScore W3201609279C72563966 @default.
• W3201609279 hasConceptScore W3201609279C99454951 @default.
• W3201609279 hasLocation W32016092791 @default.
• W3201609279 hasOpenAccess W3201609279 @default.
• W3201609279 hasPrimaryLocation W32016092791 @default.
• W3201609279 hasRelatedWork W15338904 @default.
• W3201609279 hasRelatedWork W16315462 @default.
• W3201609279 hasRelatedWork W17759832 @default.
• W3201609279 hasRelatedWork W19765164 @default.
• W3201609279 hasRelatedWork W2093970 @default.
• W3201609279 hasRelatedWork W369566 @default.
• W3201609279 hasRelatedWork W5854297 @default.
• W3201609279 hasRelatedWork W8669722 @default.
• W3201609279 hasRelatedWork W9209194 @default.
• W3201609279 hasRelatedWork W7646971 @default.
• W3201609279 isParatext "false" @default.
• W3201609279 isRetracted "false" @default.
• W3201609279 magId "3201609279" @default.
• W3201609279 workType "article" @default.